Previous close | 60.33 |
Open | 60.76 |
Bid | 60.14 x 0 |
Ask | 60.20 x 0 |
Day's range | 60.76 - 60.76 |
52-week range | 60.33 - 80.14 |
Volume | |
Avg. volume | 8 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine are included in this Analyst Blog.
Deciphera Pharmaceuticals, Inc. (DCPH) and GSK are in focus on acquisition news and Q1 earnings, respectively.
Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2024 Earnings Call Transcript April 25, 2024 Gilead Sciences, Inc. beats earnings expectations. Reported EPS is $-1.32, expectations were $-1.49. Gilead Sciences, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, everyone, and […]